Douglas S Scherr, MD

Professor of Urology

Contact & profiles

Appointments

Past Appointments

Show all 6

Centers

Education

M.D., Medicine
George Washington University School of Medicine and Health Sciences, 1994
B.A., Government and Public Policy
Cornell University, 1989

Highlights

1
Urologic oncology · 2022
DSDouglas S Scherr
PMID: 35034804DOISenior author17 citations
2
Clinical genitourinary cancer · 2021
CGChristopher Gaffney DSDouglas S Scherr
PMID: 35039232DOISenior author
3
Urology · 2021
BABashir Al Hussein JEJonathan E. Shoag SSShahrokh Shariat DSDouglas S Scherr
PMID: 33766715DOISenior author3 citations

297

3 grants

Co-I
Pelvic fascia spARing radical prostatectomy TrIAL (PARTIAL)
National Cancer Institute · 2022–2028
R01CA259173-02
MPI
Development of Predictive Biomarkers for Response to EV-Pembrolizumab in Bladder Cancer || Fellow: John Heard
New York Academy of Medicine · 2026–2027
NYAM 260201-01
Co-I
Optimizing automated patient-centered summaries of prostatectomy pathology reports Fellow: Parsa Iranmahboub
New York Academy of Medicine · 2026–2026
NYAM 260289-01

Completed grants (5)

PI
Design and optimization of cell therapy for use in bladder cancer
New York Academy of Medicine · 2023–2024
NYAM 230268-01
Co-I
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-05
PI
Targeting Endoplasmic Reticulum Stress and the Unfolded Protein Response in a murine bladder cancer model
New York Academy of Medicine · 2020–2022
NYAM 202577-02
PI
A Novel Approach to PSMA-positive Prostate Cancer: Tumor Replacement Therapy
New York Academy of Medicine · 2020–2021Fellowship
NYAM 202630-01
Sub-PI
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
National Cancer Institute · 2010–2015 · via Emory University· 2 renewals
U01CA113913-09

2 studies

PI
Assessment of large language model guidance for management of patients with prostate cancer
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
PI
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
PHASE3 · Southwest Oncology Group · OPEN TO ACCRUAL (as of 2025)
Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
NCT03678025

Completed & closed trials (6)

PI
Molecular Profiling of Urologic Cancers
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
PI
A Rollover Study to Follow the Durability of Response for Patients from Study UT001 (Formerly TC-UT-03, Post-marketing Commitment) and Study TC-BC-12
UroGen Pharma Ltd. · IRB STUDY CLOSURE (as of 2025)
PI
Assessment of health disparities and implicit bias in the management of patients with Prostate Cancer
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
Evaluation of the Microbiome in Genitourinary Malignancies
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)
PI
A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence
PHASE2 · UroGen Pharma Ltd. · IRB STUDY CLOSURE (as of 2021)
Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder
NCT03558503
PI
A Phase 2 Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin
PHASE2 · Anchiano Therapeutics · IRB STUDY CLOSURE (as of 2020)
Non-muscle Invasive Bladder Cancer (NMIBC)
NCT03719300